Dr. Reddy’s Laboratories Ltd. announced the signing of a deal to divest certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited. Under the agreement, Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy’s for a consideration of Rs. 275 cr. As per IQVIA MAT December 2022,…
Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited. The portfolio includes approximately 45 commercial products, four pipeline…
Dr. Reddy’s Laboratories Ltd. announced that it has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals, Inc. The portfolio includes the Biorphen (phenylephrine hydrocholoride) Injection and Rezipres (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one firstto-file approved ANDA for Cysteine Hydrochloride…
Dr. Reddy’s Laboratories Limited announced the appointment of Penny Wan to its Board of Directors, effective January 28, 2022. According to the company’s exchange filing, “we would like to inform you that Ms Penny Wan (DIN: 09479493) has been appointed as an Additional Director, categorized as Independent, on the Board of Dr. Reddy’s Laboratories Ltd.,…
Dr. Reddy’s Laboratories Ltd. announced that the first consignment of imported doses of the Sputnik V vaccine that landed in India on 1 st May, 2021, received regulatory clearance from the Central Drugs Laboratory, Kasauli, on 13th May, 2021. As part of a limited pilot, the soft launch of the vaccine has commenced and the…
Rahul Kapoor has joined The Himalaya Drug Company as Chief People Officer. Most recently, Kapoor served as VP & Head HR , Emerging Markets at Dr. Reddy’s Laboratories. In this new role, Kapoor will be leading the healthcare products company’s people and culture agenda globally. Kapoor brings in 21 years of experience in leading the…
Dr. Reddy’s Laboratories Ltd. announced that it has received permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act. In September 2020, Dr. Reddy’s…
Glenmark Pharmaceuticals Ltd., a research-led, integrated global pharmaceutical company, announced that it has entered into a definitive agreement with Dr. Reddy’s Laboratories Ltd. to divest its brand Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along with rights to…
Dr. Reddy’s Laboratories announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India. The partnership will allow Dr. Reddy’s to identify and use some of BIRAC’s clinical trial centres for the vaccine, which are funded under…
Dr. Reddy’s Laboratories Ltd announced that Parag Agarwal will be joining the Company as Chief Financial Officer. The Board of Directors has approved his appointment as a Chief Financial Officer of the Company effective December 1, 2020. Parag succeeds Saumen Chakraborty as CFO. In a career spanning over 33 years, Parag has held several leadership…
Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India. This will be a multicenter and randomized controlled study, which will include…
Dr. Reddy’s Laboratories has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5 °C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to further minimize environmental impact. The Company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 percent…
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd, a global pharmaceutical company headquartered out of India, announced that they have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses…
Dr. Reddy’s announced the launch of AVIGAN (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. AVIGAN (Favipiravir) has been approved by the Drugs…
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced that based on the recommendations of the Nomination, Governance and Compensation Committee, its Board of Directors have appointed GV Prasad, presently Vice-Chairman and CEO as the “Chairman and CEO” and Satish Reddy as “Vice-Chairman” in addition to his present role of Managing Director and COO, effective from…